GC Corp Signs Definitive Agreement to Acquire BioCentriq, Inc.

JPA Health Acquires BioCentric, Inc.

May 24, 2024

Healthcare Services

JPA Health, a global full-service integrated health agency, has acquired BioCentric, Inc., an award-winning medical communications agency known for scientific storytelling, clinical trial acceleration, and HCP engagement. BioCentric will become JPA Health’s medical communications and learning experiences arm, with founder Sherine Aly continuing to lead the division and offices in Collingswood, New Jersey and Lausanne, Switzerland.

Global Cord Blood Corporation Acquires Cellenkos, Inc.

April 29, 2022

Biotechnology

Global Cord Blood Corporation (GCBC) agreed to acquire 100% of clinical-stage biotech Cellenkos, Inc., and worldwide rights to most of its products (excluding those under an Incyte collaboration). The transaction consideration includes approximately 125 million new shares (as-converted) valued at $11 per share plus $664 million in cash; GCBC said the acquisition expands its capabilities into allogeneic T-reg cell therapies and supports global commercialization and R&D.

SK pharmteco Acquires Controlling Interest in Center for Breakthrough Medicines

September 19, 2023

Biotechnology

SK pharmteco is acquiring a controlling interest in cell and gene therapy CDMO Center for Breakthrough Medicines (CBM), integrating CBM with its Paris-based Yposkesi to create a global cell & gene therapy business unit. The deal expands SK pharmteco's technical capabilities, production capacity, and U.S./European footprint in advanced biologics manufacturing.

CellCarta Acquires Biogazelle

December 14, 2021

Biotechnology

CellCarta has acquired Biogazelle, a Ghent-based leader in digital PCR (dPCR), qPCR and RNASeq assay development, to strengthen and expand its genomic capabilities. The acquisition creates a Center of Excellence for complex genomic biomarker assay development within CellCarta and broadens its service offering for pharmaceutical and biotech clients across discovery and clinical stages.

Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)

October 4, 2022

Biotechnology

Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.

Charles River Laboratories Acquires Cognate BioServices

February 17, 2021

Biotechnology

Charles River Laboratories agreed to acquire Cognate BioServices for approximately $875 million in cash, expanding Charles River's capabilities into the high-growth cell and gene therapy CDMO sector. Cognate, headquartered in Memphis, Tennessee with over 500 employees, will provide Charles River integrated cell and gene therapy development, testing, and CGMP manufacturing capabilities; the deal was expected to close by end of Q1 2021.